| Date Filed | Type | Description |
| 08/18/2023 |
4
| Russo Rene (CEO) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Granted 700,000 options to buy
@ $2.785, valued at
$1.9M
|
|
| 08/18/2023 |
4
| Frankenfield Christopher James (COO) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Granted 300,000 options to buy
@ $2.785, valued at
$835.5k
|
|
| 08/18/2023 |
4
| Brennan Kevin M. (SVP, FINANCE AND ACCOUNTING) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Granted 25,000 options to buy
@ $2.785, valued at
$69.6k
|
|
| 08/18/2023 |
4
| Huber Martin H. Jr. (PRESIDENT AND HEAD OF R&D) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Granted 136,500 options to buy
@ $2.785, valued at
$380.2k
|
|
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Investor presentation, Quarterly results |
| 08/07/2023 |
4
| Frankenfield Christopher James (COO) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Granted 150,000 options to buy
@ $2.75, valued at
$412.5k
|
|
| 08/07/2023 |
3
| Frankenfield Christopher James (COO) has filed a Form 3 on Xilio Therapeutics, Inc. |
| 08/03/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/25/2023 |
8-K
| Investor presentation |
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Quarterly results |
| 04/25/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/25/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/25/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/03/2023 |
4
| Brennan Kevin M. (SVP, FINANCE AND ACCOUNTING) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Granted 55,000 options to buy
@ $3.17, valued at
$174.4k
|
|
| 04/03/2023 |
3
| Brennan Kevin M. (SVP, FINANCE AND ACCOUNTING) has filed a Form 3 on Xilio Therapeutics, Inc. |
| 04/03/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/02/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/02/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/02/2023 |
8-K
| Quarterly results |
| 02/09/2023 |
SC 13G/A
| FMR LLC reports a 6.9% stake in XILIO THERAPEUTICS INC |
| 01/25/2023 |
SC 13G
| Octagon Capital Advisors LP reports a 8.8% stake in XILIO THERAPEUTICS, INC. |
| 01/09/2023 |
8-K
| Investor presentation |
| 01/04/2023 |
4
| Russo Rene (CEO) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Granted 350,000 options to buy
@ $2.69, valued at
$941.5k
|
|
| 01/04/2023 |
4
| Huber Martin H. Jr. (PRESIDENT AND HEAD OF R&D) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Granted 136,500 options to buy
@ $2.69, valued at
$367.2k
|
|
| 01/04/2023 |
4
| English Edward C (PRINCIPAL ACCOUNTING OFFICER) has filed a Form 4 on Xilio Therapeutics, Inc.|
Txns:
| Granted 24,000 options to buy
@ $2.69, valued at
$64.6k
|
|
| 12/29/2022 |
SC 13G/A
| Flynn James E reports a 0% stake in Xilio Therapeutics, Inc. |
| 11/21/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 11/16/2022 |
3
| English Edward C (Principal Accounting Officer) has filed a Form 3 on Xilio Therapeutics, Inc. |
| 11/14/2022 |
SC 13G/A
| RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in XILIO THERAPEUTICS, INC. |
| 11/09/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 11/09/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/09/2022 |
8-K
| Investor presentation, Quarterly results |
|